Search

Displaying results 1581 - 1590 of 10000 in total
  1. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for

    Products: Adempas 2 mg film-coated tablet, PULLMOGUAT® 2 MG TABLETA RECUBIERTA
  2. Drug

    Brompheniramine

    go.drugbank.com/drugs/DB00835
    Approved

    Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.

    Mixtures: M-end Wc, M-end PEProducts: BOMEX TABLET 4 mg, Dimegan Inj 10mg/ml
  3. Drug

    Fenofibric acid

    go.drugbank.com/drugs/DB13873
    ApprovedInvestigational

    Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia.

    Mixtures: FENOVAS®10 MG, FENOVAS®10 MGProducts: TRILIPIX 135 MG, ACIDO FENOFIBRICO 135 MG
  4. Drug

    Strontium ranelate

    go.drugbank.com/drugs/DB09267
    ApprovedWithdrawn

    Available for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … Strontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis.

    Mixtures: STRODAY D3 2G/800 IU SAŞE , 28 SAŞE, FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 30 ADETProducts: RASBY 2 G ORAL SUSPANSIYON ICIN GRANUL ,100 PAKET, DIOSS 2 G EFERVESAN TABLET, 56 ADET
  5. Drug

    Bosentan

    go.drugbank.com/drugs/DB00559
    ApprovedInvestigational

    Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals.

    Products: N/A, BOSENTAN AL 125MG FTA
  6. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor. … [L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: NİNLARO 2.3 MG MG KAPSÜL, 3 ADET, NINLARO® 3.0 MG
  7. Drug

    Brexpiprazole

    go.drugbank.com/drugs/DB09128
    ApprovedInvestigational

    [A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. … Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM).

    Synonyms: Lu-AF41156Products: REXULTI (BREXPIPRAZOLE) TABLETS 1 MG, REXULTI (BREXPIPRAZOLE) TABLETS 2 MG
  8. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. … Rotigotine has been authorized as a treatment for RLS since August 2008.

    Products: NEUPRO® 6 MG/24 H, NEUPRO® 4 MG /24 H
  9. Drug

    Fgi-101-1a6

    go.drugbank.com/drugs/DB33756
    Investigational

  10. Drug

    Maprotiline

    go.drugbank.com/drugs/DB00934
    Approved

    Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs).

    Products: MAPROTILIN-NEURAX 25 MG, MAPROTILIN-NEURAX 50 MG